« Return to News | CROs/Service Providers | Drug Sponsors

GNS Healthcare, Covance to enable more efficient, cost-effective drug development

Friday, September 21, 2012 02:31 PM

GNS Healthcare, a Cambridge, Mass.-based healthcare data analytics company focused on enabling personalized medicine, has entered into a collaboration with global CRO Covance to develop novel data-driven models that will assist pharmaceutical companies in optimizing the efficiency and cost-effectiveness of drug development activities.

Combining GNS's supercomputer-driven REFS (Reverse Engineering and Forward Simulation) big data analytics platform and Covance's data assets derived from its extensive clinical and scientific support of pharmaceutical drug development, the companies will create computer models that predict the likelihood of development success for a drug candidate given available safety and efficacy data across a variety of patient characteristics, across many diseases, starting with type 2 diabetes. Financial terms of the agreement were not disclosed.

"Our collaboration with Covance combines our unique collective resources and capabilities to tackle what has previously been an intractable challenge—improving dismal clinical drug development success rates," said Colin Hill, president, CEO and co-founder of GNS Healthcare. "The predictive computer models arising from our collaboration will address this problem and will in turn lead to better treatment options for patients.”

The collaboration complements GNS' existing work with several major pharmaceutical companies in creating treatment algorithms to match patients to drugs and to discover novel biomarkers from wide-ranging molecular and clinical trial data.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.